Drugs Made In America Acquisition II Corp.

What they do

The company is a shell company incorporated on August 23, 2024 with no operations and no revenue; its assets consist almost entirely of cash held in a trust account. It was formed to effect a merger, share exchange, asset acquisition, share purchase, recapitalization, reorganization or similar business combination with one or more businesses. While it may pursue a target in any industry or geography, it intends to focus its search on the pharmaceutical industry.

Revenue drivers

• Trust account interest income — The only source of income described; $500,000,000 of IPO and private placement proceeds were placed in a trust account, and interest earned that is not released to the company is the sole economic return, with no operating revenue.
• No operating segments — The company has neither engaged in any operations nor generated any revenue to date, so there are no product lines or business segments to size.

Recent performance

Annual net income for 2025 was $4.2 million, while operating cash flow for 2025 was negative $1.0 million. As of June 30, 2026, total assets were $514.1 million, total liabilities were $18.1 million, and shareholder equity was negative $17.9 million. Cash and equivalents at June 30, 2026 were only $174,974, with the bulk of capital held in the trust account. The company reported no revenue in any period.

Strategy

Management intends to use cash from the IPO and private placement, plus shares and debt, to complete an initial business combination, focusing its search on the pharmaceutical industry. The company has up to 24 months from the September 26, 2025 IPO closing to consummate a business combination. If it fails to do so, it will redeem 100% of public shares for a pro rata portion of trust account funds and then seek to liquidate and dissolve.

Risks

• No operating business or revenue — The company is a shell with no operations and nominal assets consisting almost entirely of cash, so it has no earnings stream to support its valuation or obligations.
• 24-month combination deadline — If it does not consummate an initial business combination within 24 months of the September 26, 2025 IPO closing, it must redeem all public shares and liquidate.
• Low unrestricted cash — Cash and equivalents were only $174,974 as of June 30, 2026, leaving little outside the trust account to fund search, diligence and transaction costs.
• Sponsor concentration and forfeitures — The sponsor and other initial shareholders own 20% of issued and outstanding ordinary shares excluding private units; the sponsor forfeited 18,847,222 shares in February 2025 and 11,500,000 in May 2025, leaving 14,375,000 founder shares.

Outlook

Management states it expects to continue to incur significant costs in pursuit of its acquisition plans and cannot assure that its plans to complete an initial business combination will be successful. The company remains an early stage and emerging growth company subject to the risks associated with such companies. It has up to 24 months from the September 26, 2025 IPO closing to complete a combination or face redemption and liquidation.